Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H1.4 is a member of the linker histone H1 protein family, critical for chromatin structure in eukaryotic cells. Unlike core histones (H2A, H2B, H3, H4)—which create the nucleosome "bead"—H1.4 binds at the entry/exit points of DNA associated with the nucleosome and to the intervening linker DNA. This structural role enables H1.4 to mediate chromatin compaction from the “beads-on-a-string” form to a dense 30 nm fiber, influencing DNA accessibility for processes such as transcription, replication, and repair[1][2][3][4]. H1.4 consists of a conserved central globular domain and highly basic, flexible N- and C-terminal tails. These tails undergo extensive posttranslational modifications (PTMs), including methylation, acetylation, phosphorylation, and ubiquitination, which regulate the binding of effector proteins and impact chromatin states. Methylation of lysine 26 (K26) on H1.4 is particularly abundant and functions as a platform for proteins like HP1, important in heterochromatin formation and gene repression[2]. Histone H1.4, like other H1 variants, is multifunctional—regulating chromatin architecture, gene expression (primarily repression), nucleosome spacing, and facilitating the assembly or disassembly of chromatin in concert with histone chaperones and other protein partners[3]. In mammals, H1.4 is enriched in heterochromatin and less active genomic regions, in contrast to H1 variants found in actively transcribed regions. Although no drugs specifically target H1.4, its modifications—especially methylation and phosphorylation—are studied for their roles in cancer and other diseases, sometimes serving as biomarkers for pathological chromatin states[2]. Disturbed expression or modification of histone H1.4 can cause chromatin relaxation, genomic instability, and altered cell fate, making its indirect regulation a therapeutic concern, with potential risks tied to epigenetic therapies.
Not applicable (no direct drug targets; indirect actions include acetylation, methylation, phosphorylation affecting chromatin state)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H1.4 (H1.4).